Overview

• One Phase 3 trial showed a 27% reduction in moderate or severe COPD exacerbations compared with placebo at week 52.
• A second study failed to meet its primary endpoint despite earlier indications of benefit among former smokers.
• Regeneron's shares slid nearly 13% in premarket trading following the announcement of the mixed trial outcomes.
• The companies will review the full dataset and consult with regulatory authorities before deciding on next steps for itepekimab.
• Itepekimab inhibits interleukin-33 and targets former-smoker COPD patients against a backdrop of limited treatment options and nearly 16 million U.S. sufferers.